Frequently Asked Questions
The market is segmented based on , By Product Type (Bone Marrow Derived Mesenchymal Cells, Placental or Umbilical Stem Cell, Adipose Tissue Derived Mesenchymal Stem Cells, and Others), Type (Allogenic Stem Cell Therapy and Autologous Stem Cell Therapy), Application (Musculoskeletal Disorders, Acute Graft-Versus-Host Disease (AGVHD), Wounds and Injuries, Cardiovascular Diseases, Surgeries, Gastrointestinal Diseases, and Others), End User (Hospitals and Surgical Centers, Therapeutic Companies, Services Companies, and Others), Distribution Channel (Direct Tender, Third Party Distributors) – Industry Trends and Forecast to 2030.
.
The Global Stem Cell Therapy Market size was valued at USD 257.00 USD Million in 2022.
The Global Stem Cell Therapy Market is projected to grow at a CAGR of 17.3% during the forecast period of 2023 to 2030.
The major players operating in the market include , Athersys , Mesoblast Ltd , Biorestorative Therapies , Pluristem , Brainstorm Cell Limited. , ViaCyte , Gamida Cell , HOPE BIOSCIENCES , Cellular Biomedicine Group , Smith+Nephew , MEDIPOST , ANTEROGEN. C.O. , NuVasive , RTI Surgical , AlloSource , JCR Pharmaceuticals Co. , Takeda Pharmaceutical Company Limited ,.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
